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Abstract
Background: Influenza A infections have been described to cause secondary hemolytic uremic syndrome and to
trigger atypical hemolytic uremic syndrome (aHUS) in individuals with an underlying genetic complement
dysregulation. To date, influenza B has not been reported to trigger aHUS.
Case presentation: A 6-month-old boy presented with hemolytic uremic syndrome triggered by influenza B
infection. Initially the child recovered spontaneously. When he relapsed Eculizumab treatment was initiated,
resulting in complete and sustained remission. A pathogenic mutation in membrane cofactor protein (MCP) was
detected.
Conclusion: Influenza B is a trigger for aHUS and might be underreported as such. Influenza vaccination may
protect patients at risk.
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Background
Hemolytic uremic syndrome (HUS) is a thrombotic micro-
angiopathic disease characterised by thrombocytopenia,
hemolytical anemia, and renal impairment [1]. Most cases
of HUS in industrialized countries are due to infections
with pathogenic Shiga toxin-producing Escherichia coli
(STEC) with 0157:H7 being the most common serotype,
while in some tropical regions Shigella dysenteriae type I is
the leading HUS-causing pathogen [2, 3]. Beside this HUS
may be due to inborn defects of the alternative pathway
regulation of the complement system, then denominated
atypical HUS (aHUS). Around 10% of all HUS cases are
thought to be aHUS and mutations in genes encoding for
proteins in the alternative complement pathway are identi-
fied in around 50% of the patients with aHUS [4]. For
aHUS an effective treatment with Eculizumab, a monoclo-
nal anti-C5-antibody, which blocks the terminal alternative
pathway activation, is available. Furthermore, non-Shiga
toxin mediated causes of HUS have been associated with
other infectious agents, predominantly Streptococcus pneu-
moniae, but also influenza A, HIV, and others, as well as
metabolic diseases, rheumatic diseases, malignancy, preg-
nancy, radiation, and some drugs [4].
In most aHUS patients an ongoing active inflamma-
tory process causes progressive damage of the nephrons
leading to life-threatening complications and often to
end-stage renal disease. Not all children with potential
disease-causing mutations in aHUS genes develop
disease and the reasons for this phenomenon, as well as
the pathophysiological trigger mechanisms leading to
disease manifestation are not completely understood.
Influenza A is a very common human-pathogenic virus
known to directly cause secondary HUS, although
historical cases reported in the literature may actually
also have been due to yet undiscovered mutations in
complement regulator genes. However, influenza A, pre-
dominantly pandemic H1N1 Influenza A, but also
seasonal influenza A, sometimes in combination with
pneumococcal co-infection, have both clearly been
described to trigger aHUS [5]. These reports also
included patients with aHUS after H1N1-infections who
carry mutations in the gene for the complement regula-
tor membrane cofactor protein (MCP), also known as
CD46 [6]. By contrast, reports of influenza B infections
triggering aHUS are missing.
Case presentation
During the last influenza season a 6-month-old boy born
to Turkish, unrelated healthy parents, was admitted after
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5 days of febrile bronchitis and without any history of
recent diarrhea, with pallor, edema of the eyelids and
reduced urine output. Hemolytic anemia (hemoglobin
5.7 g/dL (10.1–13.1 g/dL)), thrombocytopenia (58/nL
(150–500/nL)), and renal failure with raised serum cre-
atinine (1.42 mg/dL (0.2–0.5 mg/dL)) lead to the diagno-
sis of HUS. A blood smear showed schistocytes, the
urine analysis proteinuria and an ultrasound enlarged
hyperechogenic kidneys. ADAMTS13 activity was
normal, while complement activation could be confirmed
by mildly reduced serum C3 (69 mg/dL (90–180 mg/
dL)) and increased plasma terminal complement com-
plex sC5b-9 (450 ng/ml (<320 ng/ml)). We could not
detect any pathogenic enterobacteria (enterohemorrha-
gic E. coli, Yersina-, Shigella-, Campylobacter species)
by culture and no Shiga toxin by PCR in multiple stool
samples. A nasopharyngeal swab showed presence of
Influenza B DNA by multiplex-PCR and genotyping
identified the subtype Yamagata.
Subsequently, genomic analysis of the patient’s CFH,
CFI, C3 and MCP genes by Sanger-sequencing identified
a pathogenic heterozygous mutation in the MCP gene
(c.104G > A (p.Cys35Tyr)) confirming the diagnosis of
aHUS [7]. In addition, quantitative MLPA-analysis
showed a suspicious signal of a non-allelic homologous
recombination (NAHR) in the regulators of complement
activation gene cluster (RCA) on chromosome 1 [8].
Meanwhile, we had started the patient on the antiviral
drug Oseltamivir, antihypertensive medication and
symptomatic treatment. After initial spontaneous recovery
the patient developed clinical signs of relapse. Eculizumab
treatment was started immediately after vaccination
against meningococcal diseases. This resulted in a
complete and sustained remission ever since (Fig. 1). Pre-
viously not immunized, the patient will now be vaccinated
against influenza with quadrivalent vaccines for maximum
protection before each start of the upcoming seasons.
Discussion
Atypical HUS is a rare, but severe orphan disease, which
occurs not in all individuals who are carrying distinctive
susceptibility mutations [4]. Therefore, understanding
and possibly avoiding these triggering factors is very
important. We present a case of aHUS with first onset
of disease following influenza B infection, putting a new
pathogen on the list of triggering infectious agents. Of
course it cannot be ruled out completely that disease
manifestation and influenza B infection just occurred
coincidentally. Furthermore, other unidentified factors
might have potentially played a triggering role in our
patient.
Since treatment had to be initiated while the genetic
analysis was still pending we had to take decisions based
on the clinical data. The age of disease onset was
suggestive for aHUS. There was no diarrhea and no
evidence for STEC-infection while the patient was
positive for influenza B. Influenza A and Streptococcus
pneumoniae are well known for causing secondary HUS,
Fig. 1 Parameters of disease activity in our patient and course of treatment with Eculizumab. LDH: lactate dehydrogenase, C3: complement component 3
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most likely due to viral and bacterial neuraminidases
cleaving sialic acid residues from glycoproteins on eryth-
rocytes and other surfaces of cell membranes, thereby
unmasking the Thomsen-Friedenreich antigen [9–11]. In
reports of influenza A triggering aHUS similar patho-
physiological mechanisms have been suggested but
detailed investigations or even functional analyses are
not available [11–14]. Although the genomic RNA of
influenza A and B viruses share structural similarities,
influenza B is less common than the zoonotic influenza
A virus, less genetically diverse and almost exclusively
infecting humans [15]. It seems reasonable to assume
that the viral neuraminidase of influenza B might have
pathogenic effects similar to influenza A in triggering
aHUS. Due to the relapsing course in our patient we ini-
tiated Eculizumab treatment awaiting the results of the
genetic testing and found the MCP mutations described.
MCP (CD46) is a cofactor for factor I, which is respon-
sible for the inactivation of the complement components
C3b and C4b, thereby protecting host cells from damage
by complement [16, 17]. Patients with MCP-mutations
often show a spontaneous remission, as initially in our
patient, and have a lower risk to progress to end-stage
renal disease than patients with other mutations in the
genes for regulators for the alternative pathway comple-
ment system (e.g., factor H, factor I) [2]. Therefore, after
initial weekly Eculizumab infusions, we increased the
treatment intervals to every three to 4 weeks due to the
stable condition of the patient. Possibly the patient could
be withdrawn form Eculizumab treatment in the future.
Importantly, influenza A and B are both vaccine-
preventable diseases but it remains an unanswered ques-
tion if timely influenza vaccination (which included the
B/Massachusetts/2/2012-like virus (Yamagata clade 2))
before disease manifestation in our patient, possibly also
by vaccination of the pregnant mother, might have
protected against occurrence of aHUS.
Since widespread seasonal influenza epidemics affect
huge parts of the human population every year, causing
substantial morbidity and mortality, pediatric infectious
disease experts are calling for universal influenza vaccin-
ation for all children in Europe [18]. Protecting children
by vaccination is also an effective public health strategy
because children are identified as the drivers of influenza
epidemics by producing high viral loads and spreading
the disease to adults and high at risk populations. Most
European countries already recommend influenza vac-
cination for any high-risk group, including children with
chronic renal disease. The influenza vaccines that have
been used until recently were only trivalent inactivated
influenza vaccines (TIV), including split virions or highly
purified H (hemagglutinin) and N (neuraminidase) parti-
cles of two different influenza A and one influenza B
strains. Quadrivalent influenza vaccines include two
influenza A and two influenza B strains to address the
problem of influenza B mismatch. Furthermore, a highly
accepted quadrivalent live attenuated influenza vaccine
(LAIV) for children who do not have contraindications
or precautions to this intranasal vaccine is also available.
Recent analysis from Canada and the United Kingdom
showed that replacement of TIV and trivalent LAIV with
quadrivalent influenza vaccines might also be cost-
effective [19].
Of course, only one case report of influenza B trig-
gered aHUS might not justify the strategy mentioned
above, especially as aHUS may also have occurred by
another triggering event. On the other hand influenza B
triggered aHUS may be underestimated and vaccination
protective. The aHUS registry or other HUS databases
might be able to retrospectively analyze information on
safety and efficacy of influenza vaccination [20]. It might
also be worth to conduct a prospective study evaluating
influenza vaccination strategies in this special population
to optimize care of patients with aHUS.
Conclusion
Influenza B is a trigger for aHUS and might be underre-
ported as such. Strategies of universal quadrivalent influ-
enza vaccination may protect patients at risk for aHUS.
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